Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).
Andrew B. Nixon(Duke University), Herbert I. Hurwitz(Duke Medical Center), Alexander B. Sibley(Duke University), Kouros Owzar(Duke University), Yingmiao Liu(Duke Medical Center), Alan P. Venook(University of California, San Francisco), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Federico Innocenti(AbbVie (United States)), Flora Mulkey(Sherwin Williams (United States)), Mark D. Starr(Duke Medical Center), Donna Niedzwiecki(Duke University), Ace J. Hatch(Duke Medical Center), Chen Jiang, Bert H. O’Neil(Indiana University Health), John C. Brady(Duke Medical Center), Howard S. Höchster(Rutgers, The State University of New Jersey)
Cited by 15
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k